Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder by Tan, Aaron et al.
City University of New York (CUNY) 
CUNY Academic Works 
Publications and Research Hunter College 
2019 
Effects of the KCNQ channel opener ezogabine on functional 
connectivity of the ventral striatum and clinical symptoms in 
patients with major depressive disorder 
Aaron Tan 
Icahn School of Medicine at Mount Sinai 
Sara Costi 
Icahn School of Medicine at Mount Sinai 
Laurel S. Morris 
Icahn School of Medicine at Mount Sinai 
Nicholas T. Van Dam 
Icahn School of Medicine at Mount Sinai 
Marin Kautz 
Icahn School of Medicine at Mount Sinai 
See next page for additional authors 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/hc_pubs/532 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Authors 
Aaron Tan, Sara Costi, Laurel S. Morris, Nicholas T. Van Dam, Marin Kautz, Alexis E. Whitton, Allyson K. 
Friedman, Katherine A. Collins, Gabriella Ahle, Nisha Chadha, Brian Do, Diego A. Pizzagalli, Dan V. 
Iosifescu, Eric J. Nestler, Ming-Hu Han, and James W. Murrough 
This article is available at CUNY Academic Works: https://academicworks.cuny.edu/hc_pubs/532 
Effects of the KCNQ channel opener ezogabine on functional 
connectivity of the ventral striatum and clinical symptoms in 
patients with major depressive disorder
Aaron Tan, BA#1,2, Sara Costi, MD#1, Laurel S. Morris, PhD1, Nicholas T. Van Dam, PhD1,3, 
Marin Kautz, BA1, Alexis E. Whitton, PhD4, Allyson K. Friedman, PhD5, Katherine A. 
Collins, PhD1, Gabriella Ahle, BA6, Nisha Chadha, MD7, Brian Do, MD8, Diego A. Pizzagalli, 
PhD4, Dan V. Iosifescu, MD9,10, Eric J. Nestler, MD/PhD2,11,12, Ming-Hu Han, PhD2,11,12, and 
James W. Murrough, MD/PhD1,2,12,*
1Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at 
Mount Sinai, New York, NY, USA
2Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia
4Department of Psychiatry, Harvard Medical School, Belmont, MA, USA
5Department of Biological Sciences, Hunter College, The City University of New York, New York, 
NY, USA
6Department of Psychology, Thomas Jefferson University, Philadelphia, PA, USA
7Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
8Roski Eye Institute, Keck School of Medicine at the University of Southern California, Los 
Angeles, CA, USA.
9Department of Psychiatry, New York University School of Medicine, New York, NY, USA
10Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
*To Whom Correspondence Should Be Addressed: James Murrough, M.D., Ph.D., Mood and Anxiety Disorders Program, Department 
of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10029, USA, Ph: 
(212) 241-7574, Fax: (212) 241-3354, james.murrough@mssm.edu. 
CONFLICT OF INTEREST
In the past 5 years, Dr. Murrough has provided consultation services to Sage Therapeutics, Novartis, Allergan, Fortress Biotech, 
Janssen Research and Development, Genentech, MedAvante-ProPhase, and Global Medical Education (GME) and has received 
research support from Avanir Pharmaceuticals, Inc. Dr. Murrough is named on a patent pending for neuropeptide Y as a treatment for 
mood and anxiety disorders. The Icahn School of Medicine (employer of Dr. Murrough) is named on a patent and has entered into a 
licensing agreement and will receive payments related to the use of ketamine if it is approved for the treatment of depression. Dr. 
Murrough is not named on this patent and will not receive any payments. Dr. Collins has received consulting fees from MedAvante-
ProPhase for services unrelated to this study. In the past three years, Dr. Pizzagalli received consulting fees from Akili Interactive 
Labs, BlackThorn Therapeutics, Boehreinger Ingelheim, Pfizer, and Posit Science for activities unrelated to the present study. In the 
past three years, Dr. Iosifescu has provided consultations to Alkermes, Axsome, MyndAnalytics (CNS Response), Jazz, Lundbeck, 
Otsuka, Sunovion, and has received research support (through his academic institutions) from Alkermes, Astra Zeneca, Brainsway, 
LiteCure, Neosync, Roche, and Shire. All other authors declare no conflicts of interest.
HHS Public Access
Author manuscript
Mol Psychiatry. Author manuscript; available in PMC 2019 May 02.Author M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, 
NY, USA
12Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
#
 These authors contributed equally to this work.
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet current treatment 
strategies remain limited in their mechanistic diversity. Recent evidence has highlighted a 
promising novel pharmaceutical target—the KCNQ-type potassium channel—for the treatment of 
depressive disorders, which may exert a therapeutic effect via functional changes within the brain 
reward system, including the ventral striatum. The current study assessed the effects of the KCNQ 
channel opener ezogabine (also known as retigabine) on reward circuitry and clinical symptoms in 
patients with MDD. Eighteen medication-free individuals with MDD currently in a major 
depressive episode were enrolled in an open-label study and received ezogabine up to 900 mg/day 
orally over the course of ten weeks. Resting state functional magnetic resonance imaging data 
were collected at baseline and post-treatment to examine brain reward circuitry. Reward learning 
was measured using a computerized probabilistic reward task. After treatment with ezogabine, 
subjects exhibited a significant reduction of depressive symptoms (Montgomery-Asberg 
Depression Rating Scale score change: −13.7±9.7, p<0.001, d=2.08) and anhedonic symptoms 
(Snaith-Hamilton Pleasure Scale score change: −6.1±5.3, p<0.001, d=1.00), which remained 
significant even after controlling for overall depression severity. Improvement in depression was 
associated with decreased functional connectivity between the ventral caudate and clusters within 
the mid-cingulate cortex and posterior cingulate cortex (n=14, voxel-wise p<0.005). In addition, a 
subgroup of patients tested with a probabilistic reward task (n=9) showed increased reward 
learning following treatment. These findings highlight the KCNQ-type potassium channel as a 
promising target for future drug discovery efforts in mood disorders.
INTRODUCTION
Depression is a leading cause of disability worldwide [1]. Available treatments, however, are 
only partially effective for many patients [2] and are associated with additional limitations, 
including a slow onset of therapeutic action and undesirable side effects [3,4]. Currently, the 
Food and Drug Administration (FDA)-approved treatments for depression, mostly consisting 
of serotonergic and noradrenergic agents, largely share the same basic pharmacology and 
mechanism of action based on decades-old discoveries [5]. This lack of mechanistic 
diversity leaves little opportunity for improved patient outcomes or personalized treatment 
approaches. In contrast, rational drug discovery based on a mechanistic understanding of 
disease pathology promises to deliver more effective, targeted therapies [6].
Recent preclinical evidence has highlighted the KCNQ-type voltage-gated potassium 
channel as a promising novel molecular target for the treatment of depression in a well-
validated mouse model of depression—chronic social defeat stress (CSDS) [7,8]. CSDS 
produces two distinct phenotypes—susceptible and resilient—determined by the defeated 
mouse’s willingness to interact with a novel mouse. CSDS results in an increased firing rate 
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of ventral tegmental area (VTA) dopamine neurons projecting to the nucleus accumbens 
(NAc) within the ventral striatum (VS) in rodents expressing a pro-depressive phenotype 
[7,9]. Critically, resilient animals also exhibit dysregulation within this circuit; however, they 
are able to actively counteract VTA-NAc hyperactivity by upregulating the KCNQ3 
potassium channel within the VTA [7], which serves to rebalance dopaminergic firing [10]. 
Replicating this active mechanism in susceptible mice via viral overexpression of KCNQ3 
within the reward circuit reverses the depressive behaviors, leading to a more resilient 
phenotype in rodents. Of translational importance, systemic injection of ezogabine, a 
KCNQ-selective potassium channel opener, also led to the amelioration of depressive 
behaviors in susceptible mice [8]. Taken together, this work supports the hypothesis that 
enhancing activity at KCNQ channels within the reward circuit may represent a novel 
mechanistic approach to antidepressant treatment discovery.
Based on these findings, we conducted a 10-week open-label pilot of ezogabine with the aim 
of determining if ezogabine significantly engages the reward system in human patients with 
MDD. Connectivity of the reward system was measured using resting state functional 
magnetic resonance imaging (fMRI) with the VTA and VS as regions of interest for resting 
state functional connectivity (RSFC) analysis. In addition, clinical anhedonia and reward 
learning were examined using the Snaith-Hamilton Pleasure Scale (SHAPS) and the 
probabilistic reward task (PRT) [11], respectively. Consistent with the hypothesis that 
ezogabine functions to strengthen resilience to stress [12], changes in resilience were 
measured using the Connor-Davidson Resilience Scale (CD-RISC) [13]. We hypothesized 
that modulation of the KCNQ potassium channel in humans would parallel the 
antidepressant effects found in animals, especially within the domain of reward system 
function, and would additionally normalize the connectivity of brain circuitry involved in 
depressive symptomatology. In order to assess the specificity of the effect of ezogabine on 
brain circuitry, we conducted a parallel analysis of changes in VTA and VS RSFC associated 
with antidepressant response to the glutamate N-methyl-D-aspartate (NMDA) receptor 
antagonist ketamine in a separate group of adult patients with MDD.
MATERIALS AND METHODS
Ezogabine’s Pharmacology, Brain Exposure, Safety, and Tolerability
Ezogabine is a first-in-class KCNQ-selective potassium (K+) channel opener approved by 
the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset 
seizures. Ezogabine selectively binds to and activates KCNQ transmembrane K+ ion 
channels, thereby enhancing transmembrane potassium currents mediated by the KCNQ 
(Kv7.2 to 7.5; e.g., KCNQ2/3) family of ion channels. By activating KCNQ channels, 
ezogabine is thought to stabilize the resting membrane potential and reduce brain 
excitability, likely leading to the observed anticonvulsant effect. Ezogabine is rapidly 
absorbed in 0.5 and 2 hours and readily crosses the blood-brain barrier at physiological 
concentrations and is fully metabolized primarily via glucuronidation and acetylation in 
humans with a half-life between 7 to 11 hours. The efficacy of ezogabine as adjunctive 
therapy in partial-onset seizures was established in three multicenter, randomized, double-
blind, placebo-controlled studies in 1,239 adult patients. The most common adverse effects 
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of ezogabine are dizziness (23%), drowsiness (22%) and fatigue (15%). No 
contraindications to treatment were reported in the manufacturer’s label. Since QT 
prolongation has been observed, ECG was monitored before, during and after the treatment 
with the study drug. Skin discoloration around the lips or nail bed, either blue or gray, has 
been reported and is estimated to affect up to 10% of patients treated for more than two 
years. Ezogabine carries a black box warning regarding the potential for retinal 
abnormalities following treatment with ezogabine, with an unknown relationship to vision 
loss. In June 2015, the FDA issued a safety alert stating that there was no evidence for 
treatment-associated vision loss. In keeping with FDA recommendations, study participants 
underwent full ophthalmological exams at screening and study exit [14–17]. Other side 
effects include urinary retention, neuropsychiatric symptoms (confusional state, psychotic 
symptoms, and hallucinations) and withdrawal seizures.
Study Participants and Design
The current study recruited 18 subjects 18–65 years of age with a primary diagnosis of 
MDD as assessed by the Mini-International Neuropsychiatric Interview [18]. Additional 
inclusion criteria were a score of 21 or greater on the Montgomery-Asberg Depression 
Rating Scale (MADRS) [19] and a score of at least 20 on the SHAPS [20], indicating 
moderate depression and anhedonia severity, respectively. Individuals were excluded if they 
had a lifetime history of schizophrenia, bipolar or psychotic disorder, substance use disorder 
in the preceding 6 months, unstable medical condition, retinal abnormalities, active suicidal 
or homicidal ideation, or current use of any psychotropic medications. Every subject 
underwent physical examination, clinical hematological and biochemical screening, urine 
toxicology testing, and electrocardiogram. Study participants were free of concomitant 
psychotropic medications for at least 2 weeks (4 weeks for fluoxetine) prior to 
commencement and for the duration of the study, with exceptions being a stable dose of 
zolpidem 10 mg nightly for sleep or a benzodiazepine for sleep or anxiety (dosage 
equivalent to lorazepam 1 mg daily or less). As part of the screening procedures and during 
the course of the study (midway through the treatment with ezogabine, and two weeks post-
cessation of the drug), participants underwent an ophthalmological exam according to the 
FDA recommendation, as ezogabine carries a black box warning for retinal abnormalities 
with similar features to retinal pigmental dystrophies. In addition, an electrocardiogram was 
completed midway through and at study end in order to monitor for QT interval 
prolongation, which is reported to occur with the study drug.
All study procedures were conducted at the Icahn School of Medicine at Mount Sinai in 
New York City. The institutional review board at Icahn School of Medicine at Mount Sinai 
approved the study, and written informed consent was obtained from all participants prior to 
any study procedure. Participants were compensated for their time and effort. The study is 
registered at clinicaltrials.gov (NCT02149836). Following screening, study subjects 
completed a pre-treatment assessment that included the PRT [11] and fMRI scanning 
(details below). Participants who completed the pre-treatment assessment and continued to 
meet all inclusion/exclusion criteria entered the treatment period. During this phase, 
ezogabine was titrated following the FDA guidelines until reaching the maximum target 
dose of 300mg three times daily (900mg/day) at week four. Subjects were required to 
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tolerate a minimum dose of 600mg/day in order to continue in the study. At each visit, 
participants completed self-report and clinician-administered rating scales performed by 
trained raters, and met with a study psychiatrist. The treatment period consisted of eight 
study visits, which culminated in the primary post-treatment visit, where participants 
received a second and final PRT assessment and fMRI scan. Following this visit, participants 
were instructed to taper the study medication over the following three weeks based on FDA-
recommended guidelines and returned to the clinic for a final study exit visit. The primary 
clinical post-treatment of the study was depression severity as measured by the MADRS 
administered by a trained rater. Depression was additionally measured using the Quick 
Inventory of Depressive Symptomatology–Self Report (QIDS-SR) [21], and global illness 
severity was measured using the Clinical Global Impression-Improvement/Severity (CGI-
I/S) [22]. Anhedonia was measured using the SHAPS and the Temporal Experience of 
Pleasure Scale (TEPS) [23]. Resilience was measured by the CD-RISC [13]. Safety and 
tolerability were assessed at each study visit by frequency of adverse events (AEs) and 
suicidal ideation and behavior by the Columbia Suicide Severity Rating Scale (C-SSRS) 
[24]. Medication compliance was calculated via medication reconciliation forms and pill 
count. AEs were reported according to the Medical Dictionary for Regulatory Activities 
(MeDRA) system [25].
Statistical Analysis of Clinical Data
Demographic data and clinical characteristics were analyzed using summary statistics. 
Given the small sample size, last observation carried forward (LOCF) was used for intent-to-
treat (ITT) analysis. Paired two-sided t-tests between pre-treatment (week 0) and post-
treatment (week 10) were performed on self-report questionnaires and clinician-
administrated scales. For instruments with more than two time points available for analysis, 
repeated measures analysis of variance (ANOVA) was performed. A p<0.05 was considered 
statistically significant and Bonferroni correction was utilized for repeated measures 
ANOVA analyses. No adjustment was made for multiplicity across clinical measures. The 
proportion of patients who achieved response and remission criteria was also computed, 
defined as a 50% reduction in MADRS score at study end compared to pre-treatment or a 
MADRS score below 10, respectively.
fMRI Data Acquisition, Processing, and Analysis
Imaging data were acquired using a Siemens 3T Connectome Skyra scanner (Siemens, 
Erlangen, Germany) with a 32-channel headcoil. A T1-weighted anatomical image was 
acquired at 0.8mm isotropic resolution (TR=2400ms, TE=2.07 ms, Flip Angle=8°). Resting 
state fMRI data were acquired as a set of 600 gradient-echo echo-planar images with 70 
axial slices (2.1mm isotropic resolution, no gap, TR=1,000 ms, TE=35ms, flip angle=60°, 
multiband factor=7) for 10 minutes with eyes open. Resting state fMRI data were processed 
using a combination of AFNI [26] and FSL [27] tools. Data were despiked, motion corrected 
and co-registered to their respective anatomical image. Independent component analysis-
based motion denoising was performed with ICA-AROMA [28]. Signal from white matter 
and cerebrospinal fluid were regressed out [29]. Functional data were normalized to MNI 
space and spatially smoothed with a 6mm full-width-at-half-maximum (FWHM) kernel. 
Finally, volumes were band-pass filtered between 0.01 and 0.1 Hz and detrended.
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Seed-to-whole-brain resting state functional connectivity (RSFC) was computed at pre-
treatment and post-treatment for three regions of interest: VTA, defined functionally [30], 
and bilateral ventral caudate (vCa) and NAc, defined anatomically by the Harvard-Oxford 
Atlas distributed with FSL (see Figure 2d for seeds). Within the reward circuit, we focused 
on the striatal seeds, in part due to limited signal availability at the level of the VTA [31]. 
For these analyses, we primarily examined RSFC changes that were associated with clinical 
improvement [(post-treatment – pre-treatment RSFC) × (post-treatment – pre-treatment 
MADRS/SHAPS)]. We secondarily examined (a) RSFC changes from pre-treatment to post-
treatment; (b) pre-treatment RSFC correlations with pre-treatment clinical measures; (c) pre-
treatment RSFC correlations with changes in clinical measures. These analyses were 
performed as paired or one sample two-sided t-tests with clinical measures as covariates of 
interest, and sex and age as nuisance covariates. For seed-to-whole-brain analyses, cluster-
defining thresholds were computed at an alpha level of <0.05 using AFNI’s method of 
permutation testing. For voxelwise p’s<0.01, this method adequately controls the false 
positive rate <5% and addresses the concerns that have been raised with significance testing 
of fMRI data [32,33]. We reported findings as significant for a voxelwise p<0.005, for which 
the minimum significant cluster size was determined to be 137 voxels. For the primary aim, 
Bonferroni correction was performed for a total of four comparisons (two seeds vs. change 
in MADRS/SHAPS). Pearson’s correlations between the mean RSFC of significant clusters 
and clinical measures were computed and then converted to corrected p values.
In order to assess if the primary findings are specific to the pharmacology of ezogabine, 
parallel analyses were performed on a group of 15 adult individuals with MDD who 
received a single intravenous (IV) infusion of ketamine (0.5 mg/kg) in the context of a 
separate clinical trial (clinicaltrials.gov; NCT01880593). These subjects received pre- and 
post-treatment scans with identical acquisition parameters, preprocessing pipelines, and 
analytic strategy as the subjects in the ezogabine protocol. Likewise, subjects in the 
ketamine protocol were free of concomitant antidepressant treatment and in a current major 
depressive episode. See Supplemental Material for further detail.
Probabilistic Reward Task
The PRT is a signal detection test that provides an objective assessment of reward learning 
[11]. During this computer-based task, subjects are asked to discriminate between two 
ambiguous stimuli – a short (11.5 mm) vs. long (13 mm) mouth displayed rapidly (100 ms) 
in a schematic face – in order to receive a monetary reward of 20¢. Unbeknownst to the 
subjects, correct identification of one stimulus (the “rich stimulus”) is reinforced three times 
more frequently than the other stimulus (the “lean stimulus”). Under these experimental 
circumstances, healthy subjects reliably develop a response bias for the rich stimulus, 
regardless of which stimulus was actually presented. Contrarily, subjects with MDD fail to 
develop this bias for the more frequently reinforced stimulus, and tend to respond similarly 
to both stimuli, reflecting decreased responsiveness to rewards. Discriminability was also 
calculated as a measure of more general task performance. Response bias and 
discriminability were computed using the following formulae:
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Response bias: logb = 12log
Richcorrect * Leanincorrect
Richincorrect * Leancorrect
Discriminability: logb = 12log
Richcorrect * Leancorrect
Richincorrect * Leanincorrect
The task consisted of three 100-trial blocks and was programmed in E-Prime (Version 1.1; 
Psychology Software Tools, Inc., Pittsburgh, PA). To avoid practice effects in repeated 
measures designs, two separate versions of the PRT were used and randomly assigned. The 
parameters were identical except that the target stimuli were discriminated by mouth size or 
nose size [34].
Prior to data analysis, PRT data underwent a quality control check wherein trials with below 
chance accuracy and/or >10% reaction time outliers were excluded from analysis. The 
measure of interest was change in response bias across the three Blocks of the task, as a 
function of Time (pre-treatment to post-treatment), as analyzed by repeated measures Block 
× Time ANOVA. Change in discriminability was also examined in order to ensure that 
increases in response bias were not associated with general improvements in task 
performance [11,35]. Pearson’s correlations between pre-treatment response bias (averaged 
over the latter two blocks of the task, after learning has occurred) and changes in clinical 
measures were computed to test for associations with treatment response.
RESULTS
Sample Characteristics
Of the 26 subjects assessed for eligibility, 18 met all inclusion/exclusion criteria and were 
enrolled and constituted the intent-to-treat (ITT) sample (age 51.1±9.1, 13 male). Subjects 
were in their current major depressive episode (MDE) for an average of five years and had a 
median of three lifetime MDEs; 13 had experienced recurrent MDD (Table 1). Pre-treatment 
MADRS score ranged from 21 to 38, and pre-treatment SHAPS score ranged from 27 to 51. 
Of the 18 individuals, 17 completed all study visits. One participant elected to discontinue 
the study after six weeks of treatment for unspecified reasons; all other participants 
completed the study. Across the whole sample, compliance with study medication as 
measured by pill count was 97%.
Symptom Change and Tolerability
Depressive symptoms decreased significantly from pre-treatment (week 0) to post-treatment 
(week 10) (MADRS mean change: −13.7±9.6, t17=−6.01, p<0.001, Cohen’s d=2.08) and 
throughout the study as a function of time (RM-ANOVA: F3,52=21.96, p<0.001, partial-
η2=0.56; Figure 1a). Pairwise comparisons showed a significant improvement from week 
three onwards (all p’s<0.001, Bonferroni adjusted), relative to pre-treatment. Overall, after 
ten weeks of treatment, patients showed a 45% (SD=28.9) reduction in MADRS score from 
pre-treatment to post-treatment. Likewise, QIDS-SR score was significantly reduced at study 
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end compared to pre-treatment (mean change: −5.72±4.4, t17 =−5.53, p<0.001, Cohen’s 
d=1.64). Eight out of 18 (44%) and 5 out of 18 (28%) of patient met response and remission 
criteria, respectively.
Eleven out of 18 (61%) of patients were classified as ‘much improved’ or ‘very much 
improved’ according to the CGI-I (Figure 1b). There was a significant improvement in 
anhedonia from pre-treatment to post-treatment (SHAPS mean change: −6.1±5.3, t17=4.8, 
p<0.01, Cohen’s d=1.00) and throughout the study as a function of time (F5,85=11.84, 
p<0.001, partial-η2=0.41), which remained after controlling for depression severity 
measured by the change in MADRS score calculated without the item related to anhedonia 
(Item 8: Inability to feel) (F5,80=3.03, p=0.015, partial-η2=0.16). Finally, study participants 
showed an improvement in resilience (CD-RISC mean change: 8.2±12.2, t17=2.9, p<0.01; 
pairwise comparison F3,52=3.61, p=0.02, partial-η2=0.17, Bonferroni adjusted) (Table 2).
The most common AE was dizziness, which occurred in 8 subjects. Less frequent AEs were 
confusion and headache that were reported in 3 and 2 participants, respectively. Due to the 
occurrence of AEs, three study participants failed to achieve the highest dose (900 mg/day) 
and remained at 750 mg/day (n=1) and 600 mg/day (n=2). No subjects discontinued the 
treatment protocol because of AEs, and no serious adverse events occurred during the course 
of the study. No incidents of retinal abnormalities were observed at ophthalmologist visits. A 
summary of AEs is reported in Table S1 of the supplementary material. No increase in 
suicidal ideation as measured by the C-SSRS was reported during the treatment with 
ezogabine and no participants experienced emergence of suicidal behavior during the study 
trial.
Resting State Functional Connectivity
Of the 18 subjects enrolled, 16 had a pre-treatment fMRI scan, and 14 had both a pre-
treatment and post-treatment fMRI scan. In our primary analysis, we found that 
improvement in depressive symptoms (MADRS) from pre-treatment to post-treatment was 
significantly associated with a reduction in connectivity between vCa and clusters within the 
mid-cingulate cortex (MCC) (peak z=−4.29, k=189, corrected p=0.008) and the posterior 
cingulate cortex (PCC)/precuneus (peak z=−3.82, k=170, corrected p=0.008; Figure 2a). 
Improved anhedonia (SHAPS) was similarly associated with reduced connectivity between 
vCa and both MCC (peak z=−4.87, k=411, corrected p=0.004) and PCC (peak z=−3.78, 
k=182, corrected p=0.13; Figure 2b). All results except the association between change in 
vCa-PCC RSFC and change in SHAPS survive Bonferroni correction. In the ketamine 
group, there were no significant associations between changes in vCa RSFC and changes in 
symptoms at the whole brain level. Furthermore, there were no significant associations 
between changes in vCa RSFC with the clusters reported above and respective changes in 
clinical measures (all p’s>0.4) (Supplementary Material Figure S2).
In our secondary analyses, we found that greater pre-treatment connectivity between vCa 
and MCC was significantly associated with greater improvement in depressive symptoms 
from pre-treatment to post-treatment (peak z=3.79, k=164; Figure 2c) (all voxel-wise 
p<0.005, cluster-wise α<0.05; Figure 2; MNI coordinates of cluster peaks are reported in 
Supplementary Material Table S2).
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There were no significant associations between NAc or VTA connectivity changes and 
symptom changes and there were no significant connectivity changes from pre-treatment to 
post-treatment or associations between pre-treatment connectivity and pre-treatment clinical 
measures.
Reward Learning
Sixteen subjects completed the PRT at both pre-treatment and post-treatment. Of these, 
twelve had valid pre-treatment data and nine had valid pre-treatment and post-treatment 
data. The Block × Time ANOVA revealed a main effect of Block, (F2,16=5.38, p=0.02, 
η2=0.40), where across both time points, response bias increased from blocks one to three of 
the task. A main effect of Time also emerged (F1,8=6.34, p=0.04, η2=0.44), where across 
blocks, response bias was found to be significantly higher at post-treatment compared to pre-
treatment (Figure 3a), indicating improved reward learning. No significant interaction or 
main effects emerged from the Time × Block ANOVA on discriminability (a measure of 
subject’s ability to discriminate between the stimuli that is unrelated to the asymmetrical 
reinforcement ratio), indicating that increases in response bias from pre-treatment to post-
treatment were not simply due to general improvements in task performance (all p’s>0.05). 
Finally, higher pre-treatment response bias averaged across the latter two blocks of the task 
(after learning has taken place) was associated with a greater reduction in SHAPS score 
from pre-treatment to post-treatment (r=0.64, p=0.02) (Figure 3b). This association was not 
observed with changes in overall depression severity on the MADRS (r=0.46, p=0.13), 
suggesting that pre-treatment response bias was specifically associated with treatment-
related improvements in anhedonia, but not in depressive symptoms more generally.
DISCUSSION
In the current study, we report that ezogabine, a first-in-class KCNQ channel opener, is 
associated with improvement in symptoms of depression and anhedonia in patients with 
MDD in the context of an open-label design. The improvement in anhedonia remained 
significant after controlling for change in non-anhedonia depressive symptoms, indicating 
that ezogabine may specifically target the symptom of anhedonia. A significant increase in 
resilience was observed, consistent with the hypothesis that ezogabine functions to 
strengthen resilience to stress [12]. Ezogabine was well tolerated in this sample; no SAEs 
occurred and no subjects discontinued the treatment due to AEs. Improvements in 
depression and anhedonia were associated with a reduction in functional connectivity 
between the vCa and both the MCC and the PCC at the whole-brain level, corrected. Finally, 
subjects showed evidence of increased reward learning following treatment, which may 
indicate a potential reversal of a reward learning deficit known to be associated with 
depression [35,36]. It is important to note that due to the open-label nature of this study, we 
are unable to conclude if these changes are due to the pharmacological effects of ezogabine 
or to non-specific factors, such as the placebo effect or natural variation in the underlying 
depression. In a separate group of patients with MDD who were treated with a single 
infusion of ketamine, we did not observe any changes in vCa connectivity associated with 
clinical improvement. These findings provide a preliminary indication that ezogabine may 
indeed be specifically targeting the reward system and subsequent randomized controlled 
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trials examining the effects of ezogabine or other KCNQ channel potentiators on 
neurobehavioral measures linked to depression are thereby warranted.
The current findings are consistent with the recent preclinical work that provided the 
theoretical grounds for this study. The KCNQ potassium channel was selected as a 
pharmacological target for the treatment of depression because it was upregulated in VTA 
dopamine neurons exclusively in mice resilient to CSDS. Both susceptible and resilient 
animals exhibit elevated VTA dopamine neuron excitability after CSDS, but only resilient 
animals actively engaged gene regulation mechanisms in order to reverse the phenotype [7–
10]. This belies the common characterization of resilience as the lack of pathological 
alteration. Rather, one major feature of resilience may be to actively reverse pathology. 
Induction of this active resilience mechanism in previously susceptible mice—either via 
upregulation of the KCNQ channel expression with viral vectors or enhancing existing 
channels with a KCNQ potentiator such as ezogabine—was capable of reversing their 
depressive symptoms. Our findings are also potentially consistent with preclinical studies 
that have demonstrated an association between increased BDNF release and synaptogenesis 
within the VS/NAc and depressive behaviors [37,38]. The results of the present study 
provide a preliminary demonstration for this approach and argue for the development of 
KCNQ channel potentiators that are more selective for channel isoforms enriched in the 
VTA and other limbic brain structures.
Effects of ezogabine appear to relate to modulation of a striatal-mid cingulate network. 
Although it has been argued that affective functions are localized to the rostral cingulate, 
while cognitive and motor functions are localized to the MCC [39,40], recent observations 
have implicated the MCC in a diverse array of functions including pain, negative affect and 
social processing [41,42]. The MCC is heavily connected with the caudate and the midbrain 
dopaminergic system, which are implicated not only in the incentive salience of appetitive, 
but also aversive stimuli [43–45]. Indeed, depressed patients show greater connectivity 
between the ventral striatum and MCC during loss versus win and disappointment versus 
win processing in a reward task [46]. Overall, the MCC seems to act as a hub that integrates 
affective information with cognitive control and motor centers for the expression of goal-
directed behavior [41]. Taken together, our data suggest that ezogabine may function by 
facilitating decoupling between the ventral striatal reinforcement and MCC pain and 
negative affect systems.
The current study also implicated the PCC and precuneus in the neurobiological effects of 
ezogabine. These regions are the posterior elements of the default mode network and are 
thought to support episodic recollection while subjects engage in spontaneous cognition 
[47]. In an activation likelihood estimate meta-analysis of resting state fMRI in MDD, the 
anterior precuneus was found to be hyperactive [48]. Additionally, default mode dominance 
over task positive networks has been associated with a tendency towards maladaptive 
rumination as opposed to adaptive reflection[49]. Compared to healthy controls, depressed 
subjects exhibit elevated PCC response to emotional stimuli [50], and similar to the MCC, 
depressed subjects exhibit increased connectivity between the ventral striatum and 
precuneus during disappointment versus win processing in a reward task [46]. As with the 
MCC, we propose that ezogabine may function by decoupling the ventral striatal 
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reinforcement system from the PCC and precuneus, regions associated with maladaptive 
rumination and dysfunctional reward and emotional processing.
Ezogabine significantly improved reward learning as measured by the PRT. Subjects with 
MDD and healthy subjects with depressive symptoms show evidence of a more blunted 
response bias on this paradigm, reflecting a decreased responsiveness to reward. Thus, 
evidence of a significant increase in the strength of this bias from pre-treatment to post-
treatment is suggestive of an improvement in reward sensitivity and a greater ability to 
modulate behavior as a function of reinforcement. Likewise, we observed that a greater 
response bias at pre-treatment was associated greater improvement in anhedonic symptoms. 
This finding mirrors those from prior studies showing that greater response bias at pre-
treatment predicts response to eight weeks of pharmacotherapy (as clinically indicated) [36].
The current study had several limitations. Firstly, the small sample size, broad age range, 
and lack of control or placebo group limit conclusions regarding efficacy and 
generalizability. Although we did find that changes in neurocircuitry were associated with 
symptom change, there was not a main effect of time. Without placebo and non-treatment 
control groups, we are unable to distinguish between the specific pharmacological effects of 
ezogabine from non-specific factors. These non-specific factors may include patient 
expectation or natural variation in the depressive symptoms over time. Thus, we are unable 
to conclude if similar circuit changes would have been observed in the absence of drug 
treatment. To partially address the issue of the specificity of the observed effect of 
ezogabine, we conducted an analysis of changes in vCa circuitry associated with changes in 
depressive symptoms in a separate study of subjects who received a single infusion of 
ketamine as a treatment for MDD. This group demonstrated no association between changes 
in vCa connectivity and improvement in depression. While the inclusion of these results 
allows for a qualitative comparison to changes observed with ezogabine, caution is 
warranted in interpreting these results since these analyses do not represent a head-to-head 
comparison between the two treatments. In particular, subjects in the ketamine group were 
enrolled on the basis of having failed to respond to two or more adequate trials of an 
antidepressant medication and their course of treatment occurred on a different timescale. 
Additionally, we did not find any significant associations between VTA connectivity and 
clinical measures, which may have been due to a combination of our small sample size and 
the relatively poorer fMRI signal (and therefore smaller effects) of midbrain structures. As a 
separate potential limitation, it was unexpected that the vCa rather than the NAc was the 
mediator of the effects of ezogabine. Reduced signal strength in the region of the NAc may 
have prevented us from detecting a true effect. However, given that the vCa also receives 
dopaminergic innervation from the midbrain, which would be affected by KCNQ channel 
modulation, it is possible that the vCa is also an important mediator of ezogabine’s 
antidepressant action. The striatum is organized as a series of spirals that proceed from a 
medial to lateral gradient, in which medial areas subserve limbic functions, central areas 
subserve cognitive functions, and lateral areas subserve motor functions [51]. The location 
of the vCa between medial and central areas implicates it in mediating between limbic and 
cognitive systems [52].
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In conclusion, this is the first study investigating the antidepressant effect of the KCNQ-
selective channel potentiator ezogabine in subjects with MDD. Ezogabine was associated 
with an improvement in depressive and anhedonic symptoms and exhibited good tolerability. 
Based on the findings of this preliminary study, future randomized controlled trials of 
ezogabine in depressive disorders are warranted. Understanding ezogabine’s mechanism of 
action in the human brain could lead to additional novel treatments of depression focused on 
promoting active biological mechanisms of resilience, rather than reversing the pathological 
changes associated with the syndrome, which has dominated antidepressant drug discovery 
efforts to date. These resilience-enhancing or, ‘active antidepressant’ strategies may open up 
new avenues of drug discovery for mood disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Change in Clinical Outcomes in Patients with Major Depressive Disorder Treated with 
the KCNQ Channel Opener Ezogabine.
(a) Mean MADRS and QIDS-SR score (± SEM) over time during course of ezogabine 
treatment. MADRS score decreased significantly from pre-treatment (week 0) to post-
treatment (week 10) (mean change: −13.7±9.6, t17=−6.01, p<0.001, Cohen’s d=2.08) and 
throughout the study as a function of time (RM-ANOVA: F3,52=21.96, p<0.001, partial-
η2=0.56). Likewise, QIDS-SR score was significantly reduced at study end compared to pre-
treatment (mean change: −5.72±4.4, t17 =−5.53, p<0.001, Cohen’s d=1.64). (b) CGI-I 
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category at study post-treatment. Eleven out of 18 (61%) of patients were classified as 
‘much improved’ or ‘very much improved’ according to the CGI-I.
CGI-I, Clinical Global Impression—Improvement; MADRS, Montgomery-Asberg 
Depression Rating Scale; QIDS-SR, Quick Inventory of Depression-Self Report.
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Figure 2. Functional Connectivity of the Ventral Caudate in Patients with Major Depressive 
Disorder Treated with the KCNQ Channel Opener Ezogabine.
(a) Clusters where reduction of RSFC with the vCa significantly correlated with reduction in 
MADRS score. (b) Clusters where reduction in RSFC with the vCa significantly correlated 
with reduction in SHAPS score. (c) Cluster where increased pre-treatment RSFC with the 
vCa significantly correlated with reduction in MADRS scores. (d) vCa, NAc, and VTA 
seeds, 3D view. Yellow: vCa, Blue: NAc, Red: VTA.
MADRS, Montgomery-Asberg Depression Rating Scale; NAc, nucleus accumbens; PCC, 
posterior cingulate cortex; RSFC, resting state functional connectivity; SHAPS, Snaith-
Hamilton Pleasure Scale; vCa, ventral caudate; VTA, ventral tegmental area.
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Figure 3. Change in Reward Learning and Association with Anhedonia in Patients with Major 
Depressive Disorder Treated with the KCNQ Channel Opener Ezogabine.
(a) Mean (± SEM) response bias across the three blocks of the PRT at pre-treatment and 
post-treatment. The main effect of block was significant due to a significant increase in 
response bias across blocks, indicating that the asymmetrical reinforcement ratio was 
successful at inducing a behavioral response bias (F2,16=5.38, p=0.02, η2=0.40). 
Furthermore, the main effect of time was significant due to a significant increase in overall 
response bias from pre-treatment to post-treatment, indicating that treatment improved the 
ability to modulate behavior based on prior reinforcement (F1,8=6.34, p=0.04, η2=0.44). (b) 
Higher pre-treatment response bias averaged across blocks 2 and 3 was associated with 
greater improvements in anhedonic symptom severity on the SHAPS following treatment 
(r=0.64, p=0.04).
SHAPS, Snaith-Hamilon Pleasure Scale.
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Table 1.
Demographic and clinical characteristics of the sample (n = 18).
Demographic Characteristics
Age, M (SD) 51.1 (9.1)
Male, n Male (%) 13 (72.2)
Race/Ethnicity, n (%)
 White/Caucasian 6 (33.3)
 Black/African American 10 (55.5)
 Hispanic/Latino 2 (11.1)
Employment, n (%)
 Full-Time 2 (11.1)
 Part-Time 5 (27.8)
 Retired 1 (5.6)
 Unemployed 10 (55.6)
Educational Attainment, n (%)
 Not graduated from High School 1 (5.6)
 High School 2 (11.1)
 Some College (some college + 2 year college) 7 (38.9)
 College 2 (11.1)
 Some Graduate/Professional 2 (11.1)
 Graduate/Professional 3 (16.7)
Relationship Status, n (%)
 Widowed 1 (5.6)
 Divorced/Separated 5 (27.8)
 Single, Never Married 12 (66.7)
Depression Characteristics
Baseline QIDS-SR, M (SD) 13.8 (3.2)
Baseline MADRS, M (SD) 29.5 (4.9)
Number of Depressive Episodes, M (SD) 3.1 (2.2)
Age at First Depressive Episode, M (SD) 31.2 (16.5)
Current Depressive Episode
 Age at Onset, M (SD) 45.9 (10.1)
 Duration in Months, M (SD) 61.4 (85.2)
Chronic Depression, n (%) 10 (55.6)
Recurrent Depression, n (%) 13 (72.2)
Psychiatric Characteristics
Anxiety Disorder, n (%) 7 (38.9)
PTSD, n (%) 2 (11.1)
Past EtOH Use Disorder, n (%) 4 (22.2)
Abbreviations: EtOH, ethyl alcohol; MADRS, Montgomery–Åsberg Depression Rating Scale; PTSD, Post-Traumatic Stress Disorder; QIDS-SR, 
Quick Inventory of Depressive Symptomatology-Self-Report.
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Table 2.
Additional outcome measures (n = 18).
Measure Mean Changea Standard Deviation Statistic p-value Cohen’s d
SHAPS −6.06 5.34 t17 = −4.81 <0.001 1.00
TEPS-ANT 5.06 6.49 t17 = 3.03 0.004 0.50
TEPS-CON 5.28 7.58 t17 = 2.96 0.009 0.62
CGI-S −1.56 1.25 t17 = −5.29 < 0.001 1.80
CGI-I −1.72 0.96 t17 = −7.62 < 0.001 2.54
CD-RISC 8.22 12.16 t17 = 2.87 0.011 0.49
a
Mean change = study end – baseline.
Abbreviations: CD-RISC, Connor-Davidson Resilience Scale; CGI-I/S, Clinical Global Impression – Improvement/Severity; MADRS, 
Montgomery–Åsberg Depression Rating Scale; QIDS, Quick Inventory of Depressive Symptomatology; SHAPS, Snaith-Hamilton Pleasure Scale; 
TEPS-ANT, Temporal Experience of Pleasure Scale – Anticipatory; TEPS-CON, Temporal Experience of Pleasure Scale – Consummatory.
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